HC Wainwright Forecasts Stronger Earnings for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Gossamer Bio in a research report issued on Monday, September 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($3.81) for the quarter, up from their prior forecast of ($4.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($32.80) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2026 earnings at ($1.95) EPS, FY2026 earnings at ($21.00) EPS, Q1 2027 earnings at ($1.82) EPS, Q2 2027 earnings at ($1.85) EPS, Q3 2027 earnings at ($1.08) EPS, Q4 2027 earnings at ($1.10) EPS, FY2027 earnings at ($5.64) EPS, FY2028 earnings at ($4.16) EPS, FY2029 earnings at ($1.48) EPS and FY2030 earnings at $2.60 EPS.

Several other analysts have also issued reports on GOSS. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $256.00.

Gossamer Bio Trading Up 3.6%

NASDAQ GOSS opened at $11.69 on Wednesday. The firm has a market capitalization of $34.30 million, a P/E ratio of -0.21 and a beta of 2.00. The business has a fifty day simple moving average of $13.12 and a 200 day simple moving average of $19.95. Gossamer Bio has a 12 month low of $9.10 and a 12 month high of $309.60.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Eaton Financial Holdings Company LLC purchased a new position in shares of Gossamer Bio in the fourth quarter valued at about $44,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Gossamer Bio by 22.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after purchasing an additional 4,771 shares in the last quarter. ProShare Advisors LLC raised its stake in Gossamer Bio by 39.6% during the fourth quarter. ProShare Advisors LLC now owns 45,338 shares of the company’s stock valued at $141,000 after buying an additional 12,863 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of Gossamer Bio by 496.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after purchasing an additional 50,666 shares during the last quarter. Finally, AXQ Capital LP lifted its stake in shares of Gossamer Bio by 36.1% in the fourth quarter. AXQ Capital LP now owns 63,117 shares of the company’s stock worth $196,000 after buying an additional 16,750 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

More Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for several periods, including Q3 2026, Q2–Q4 2027, FY2027, FY2028 and FY2029. The FY2027 loss estimate improved to $5.64 per share from $7.20, while the FY2029 loss estimate narrowed to $1.48 from $2.40, suggesting analysts see improving profitability over time.
• Positive Sentiment: The analyst’s long-term model still projects Gossamer Bio reaching positive earnings by FY2030, at an estimated $2.60 per share, despite a reduction from the previous $4.00 forecast.
• Neutral Sentiment: Gossamer Bio remains a highly speculative biotechnology stock, with a very small market capitalization and significant share-price volatility. The company’s current full-year consensus estimate calls for a $32.80-per-share loss, underscoring the importance of future clinical and business developments. Gossamer Bio stock gains in the latest quote
• Negative Sentiment: HC Wainwright lowered its estimates for FY2026, Q4 2026 and Q1 2027, indicating somewhat weaker near-term earnings expectations. It also cut the FY2030 forecast from $4.00 to $2.60 per share, tempering the longer-term upside case.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.